ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer
Open accessThe DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: ETS transcription factors regulate important signaling pathways involved in cell differentiation and development in many tissues and have emerged as important players in prostate cancer. However, the biological impact of ETS factors in prostate tumorigenesis is still debated. METHODOLOGY/PRINCIPAL FINDINGS: We performed an analysis of the ETS gene family using microarray data and real-time PCR in normal and tumor tissues along with functional studies in normal and cancer cell lines to understand the impact in prostate tumorigenesis and identify key targets of these transcription factors. We found frequent dysregulation of ETS genes with oncogenic (i.e., ERG and ESE1) and tumor suppressor (i.e., ESE3) properties in prostate tumors compared to normal prostate. Tumor subgroups (i.e., ERG(high), ESE1(high), ESE3(low) and NoETS tumors) were identified on the basis of their ETS expression status and showed distinct transcriptional and biological features. ERG(high) and ESE3(low) tumors had the most robust gene signatures with both distinct and overlapping features. Integrating genomic data with functional studies in multiple cell lines, we demonstrated that ERG and ESE3 controlled in opposite direction transcription of the Polycomb Group protein EZH2, a key gene in development, differentiation, stem cell biology and tumorigenesis. We further demonstrated that the prostate-specific tumor suppressor gene Nkx3.1 was controlled by ERG and ESE3 both directly and through induction of EZH2. CONCLUSIONS/SIGNIFICANCE: These findings provide new insights into the role of the ETS transcriptional network in prostate tumorigenesis and uncover previously unrecognized links between aberrant expression of ETS factors, deregulation of epigenetic effectors and silencing of tumor suppressor genes. The link between aberrant ETS activity and epigenetic gene silencing may be relevant for the clinical management of prostate cancer and design of new therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the chromosome rearrangements described above, there is mounting evidence for an oncogenic role for dysregulation of ETS genes in prostate (188, 188a), melanoma (189), and gastrointestinal stromal tumors (140).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [188]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro
Liang, C.-C., Park, A. Y., & Guan, J.-L. (2007) · Nature Protocols · doi:10.1038/nprot.2007.30 · Cited by 4,696 · cited 1×
“Cell migration was assessed using the scratch wound healing assay [47].”
MethodRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 1×
“EZH2 is up-regulated in many cancers, including clinically localized and metastatic prostate cancers [19,37].”
BackgroundPolycomb complexes repress developmental regulators in murine embryonic stem cells
Boyer, L. A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L. A., Lee, T. I., Levine, S. S., Wernig, M., Tajonar, A., Ray, M. K., et al. (2006) · Nature · doi:10.1038/nature04733 · Cited by 2,514 · cited 1×
“EZH2 is a key factor in the execution of development and differentiation programs as well as in maintenance of pluripotency and self-renewal of stem cells [38,39].”
BackgroundInflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621 · cited 3×
“cause of cancer death in western countries [1].”
BackgroundEZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundThe ETS-domain transcription factor family
Sharrocks, A. D. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35099076 · Cited by 1,086
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052 · cited 2×
“EZH2 expression in prostate tumors [20,21,22,23].”
BackgroundIntegrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922 · cited 2×
“This approach has been applied in previous studies [27,34].”
BackgroundResultDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844 · cited 1×
“recently attracted significant attention in prostate cancer since the identification of recurrent ETS gene rearrangements leading to their over-expression [2,3,4].”
Background
Cited by
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
“1, which is repressed via expression of ERG and is dependent on H3K27 trimethylation (Kunderfranco et al. 2010).”
BackgroundCell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.006 · Cited by 516
“FKBP5 is an established androgen-regulated gene in humans (Magee et al., 2006; Mostaghel et al., 2007) whose expression is immediately suppressed after castration but upregulated upon hormone replacement in the WT mouse prostate (Figure S5B) and downregulated in the Pten null intact and castrated prostates (Figure S5C…”
BackgroundGenomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
Koh, C. M., Bieberich, C. J., Dang, C. V., Nelson, W. G., Yegnasubramanian, S., & De Marzo, A. M. (2010) · Genes & Cancer · doi:10.1177/1947601910379132 · Cited by 296
Regulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
“Moreover, NF-Y, STAT3, and ETS transcription factors directly regulate EZH2 transcription in epithelial ovarian, colorectal, and prostate cancer cells, respectively [14-16].”
BackgroundERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer
Cai, C., Wang, H., He, H. H., Chen, S., He, L., Ma, F., Mucci, L., Wang, Q., Fiore, C., Sowalsky, A. G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66666 · Cited by 273
Epigenetics in Prostate Cancer: Biologic and Clinical Relevance
Jerónimo, C., Bastian, P. J., Bjartell, A., Carbone, G. M., Catto, J. W. F., Clark, S. J., Henrique, R., Nelson, W. G., & Shariat, S. F. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.035 · Cited by 226
“1 (through ERG overexpression) [78].”
BackgroundInfluentialSelf-citationKoh, C. M., Iwata, T., Zheng, Q., Bethel, C., Yegnasubramanian, S., & De Marzo, A. M. (2011) · Oncotarget · doi:10.18632/oncotarget.327 · Cited by 180
“reported that the ETS gene family members ERG and ESE3 could activate and repress EZH2 transcription, respectively [12, 13].”
BackgroundBaena, E., Shao, Z., Linn, D. E., Glass, K., Hamblen, M. J., Fujiwara, Y., Kim, J., Nguyen, M., Zhang, X., Godinho, F. J., et al. (2013) · Genes & Development · doi:10.1101/gad.211011.112 · Cited by 175
“Thus, the expression pattern of ETS members through development varies, along with their repertoire of target genes, biological processes regulated, and oncogenic potentials (Seth andWatson 2005; Kunderfranco et al. 2010; Wei et al. 2010; Hollenhorst et al. 2011).”
BackgroundZhang, J.-G., Guo, J.-F., Liu, D.-L., Liu, Q., & Wang, J.-J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318208eb35 · Cited by 173
Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells
Hollenhorst, P. C., Ferris, M. W., Hull, M. A., Chae, H., Kim, S., & Graves, B. J. (2011) · Genes & Development · doi:10.1101/gad.17546311 · Cited by 154
The molecular and cellular origin of human prostate cancer
Packer, J. R., & Maitland, N. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.02.016 · Cited by 241
Diverse involvement of EZH2 in cancer epigenetics.
Völkel, P., Dupret, B., Bourhis, X. L., & Angrand, P. (2015) · PubMed Central · Cited by 175
Börno, S. T., Fischer, A., Kerick, M., Fälth, M., Laible, M., Brase, J. C., Kuner, R., Dahl, A., Grimm, C., Sayanjali, B., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0041 · Cited by 151
The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression
Babbio, F., Pistore, C., Curti, L., Castiglioni, I., Kunderfranco, P., Brino, L., Oudet, P., Seiler, R., Thalman, G., Roggero, E., et al. (2012) · Oncogene · doi:10.1038/onc.2011.641 · Cited by 149
Self-citationMolecular Pathogenesis and Progression of Prostate Cancer
Schrecengost, R. S., & Knudsen, K. E. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.04.001 · Cited by 159
ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer
Luk, I. Y., Reehorst, C. M., & Mariadason, J. M. (2018) · Molecules · doi:10.3390/molecules23092191 · Cited by 154
Krohn, A., Seidel, A., Burkhardt, L., Bachmann, F., Mäder, M., Grupp, K., Eichenauer, T., Becker, A., Adam, M., Graefen, M., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4223 · Cited by 130
Albino, D., Longoni, N., Curti, L., Grand, M. M., Pinton, S., Civenni, G., Thalmann, G. N., D’Ambrosio, G., Sarti, M., Sessa, F., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0212 · Cited by 142
“Experimental procedure and analysis of the Kunderfranco microarray data set from tumor samples (GEO accession number GSE14206) have been previously described (21).”
InfluentialSelf-citationMolecular pathways and targets in prostate cancer
Shtivelman, E., Beer, T. M., & Evans, C. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2406 · Cited by 127
“1 [7] as well as other Homeobox genes promoters [67].”
BackgroundDeb, G., Singh, A. K., & Gupta, S. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0546 · Cited by 122
“epithelial-specific ETS factor, ESE3, are important molecular players with opposing effects regulating EZH2 expression in prostate cancer cells (66).”
BackgroundPatient-specific Boolean models of signalling networks guide personalised treatments
Montagud, A., Béal, J., Tobalina, L., Traynard, P., Subramanian, V., Szalai, B., Alföldi, R., Puskás, L. G., Valencia, A., Barillot, E., et al. (2022) · eLife · doi:10.7554/elife.72626 · Cited by 117
Androgen receptor genomic regulation.
Jin, H., Kim, J., & Yu, J. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.01 · Cited by 139
“This role of ERG in inhibiting AR-mediated prostate gene expression has later been independently validated by multiple studies (95,96).”
BackgroundLongoni, N., Sarti, M., Albino, D., Civenni, G., Malek, A. V., Ortelli, E., Pinton, S., Grand, M. M., Ostano, P., D’Ambrosio, G., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4537 · Cited by 98
“the most frequently rearranged ETS gene, in patients samples previously evaluated by qRT-PCR (5), we found that ESE1/ELF3 upregulation occurred independently of ERG”
BackgroundMethodInfluentialSelf-citationERG Is a Critical Regulator of Wnt/LEF1 Signaling in Prostate Cancer
Wu, L., Zhao, J. C., Kim, J., Jin, H., Wang, C.-Y., & Yu, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0882 · Cited by 102
“abrogation of epithelial differentiation and promotion of cancerous dedifferentiation (21, 22, 25).”
BackgroundiPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?
Attwood, S. W., & Edel, M. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030288 · Cited by 107
Civenni, G., Malek, A., Albino, D., Garcia-Escudero, R., Napoli, S., Di Marco, S., Pinton, S., Sarti, M., Carbone, G. M., & Catapano, C. V. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0615 · Cited by 91
“Gene expression data analysis Prostate cancer gene expression datasets GSE14206 (34) and GSE21034 (35) were downloaded from Gene Expression Omnibus (GEO) database.”
MethodSelf-citationMicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression
Dallavalle, C., Albino, D., Civenni, G., Merulla, J., Ostano, P., Grand, M. M., Rossi, S., Losa, M., D’Ambrosio, G., Sessa, F., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86505 · Cited by 89
“Gene expression profile data from these patients were previously described (10).”
Self-citationTian, T. V., Tomavo, N., Huot, L., Flourens, A., Bonnelye, E., Flajollet, S., Hot, D., Leroy, X., de Launoit, Y., & Duterque‐Coquillaud, M. (2013) · Oncogene · doi:10.1038/onc.2013.176 · Cited by 97
“Among these genes, we noted the striking upregulation of PLAT (Tissue-type plasminogen activator), a well-known TMPRSS2:ERG target gene in PCa (4, 36, 37).”
BackgroundIntratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer
Flammiger, A., Bayer, F., Cirugeda‐Kühnert, A., Huland, H., Tennstedt, P., Simon, R., Minner, S. J. P., Bokemeyer, C., Sauter, G., Schlomm, T., et al. (2012) · Apmis · doi:10.1111/j.1600-0463.2012.02924.x · Cited by 87
Multifaceted role of EZH2 in breast and prostate tumorigenesis: Epigenetics and beyond
Deb, G., Thakur, V. S., & Gupta, S. (2013) · Epigenetics · doi:10.4161/epi.24532 · Cited by 100
Albino, D., Civenni, G., Dallavalle, C., Roos, M. M., Jahns, H., Curti, L., Rossi, S., Pinton, S., D’Ambrosio, G., Sessa, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2665 · Cited by 74
“Samples were analyzed as previously described ((16)) by qRT-PCR.”
BackgroundMethodSelf-citationVainio, P., Mpindi, J.-P., Kohonen, P. J., Fey, V., Mirtti, T. K., Alanen, K. A., Perälä, M., Kallioniemi, O., & Iljin, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039801 · Cited by 76
Epigenetics in Prostate Cancer
Albany, C., Alva, A. S., Aparicio, A. M., Singal, R., Yellapragada, S. V., Sonpavde, G., & Hahn, N. M. (2011) · Prostate Cancer · doi:10.1155/2011/580318 · Cited by 79
“Conflict of Interests The authors declare that there is no conflict of interests.”
BackgroundClinical potential of the ERG oncoprotein in prostate cancer
Rosen, P., Sesterhenn, I. A., Brassell, S. A., McLeod, D. G., Srivastava, S. K., & Dobi, A. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.10 · Cited by 66
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 65
“Additionally, MYC and ETS transcription factors in prostate cancer [113,114], NF-YA in epithelial ovarian cancer [115], and STAT3 in colorectal cancer [23] regulate EZH2 expression, while the fusion oncoprotein EWS-FLI1 induces EZH2 expression in Ewing’s sarcoma [116].”
BackgroundRole of HOTAIR in the diagnosis and prognosis of acute leukemia
Zhang, Y., Huang, S., Zhou, H., Chen, C., Tian, L.-H., & Shen, J. (2016) · Oncology Reports · doi:10.3892/or.2016.5147 · Cited by 62
Malek, A. V., Núñez, L. E., Magistri, M., Brambilla, L., Jovic, S., Carbone, G. M., Morís, F., & Catapano, C. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035130 · Cited by 66
“Human prostate cancer PC3, DU145, 22Rv1 and LNCaP cells were maintained in RPMI 1640 [39].”
Self-citationKron, K. J., Liu, L., Trudel, D., Pethe, V. V., Trachtenberg, J., Fleshner, N. E., Bapat, B. V., & van der Kwast, T. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2901 · Cited by 69
Ets homologous factor (EHF) has critical roles in epithelial dysfunction in airway disease
Fossum, S. L., Mutolo, M. J., Tugores, A., Ghosh, S., Randell, S. H., Jones, L. C., Leir, S., & Harris, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.775304 · Cited by 62
“This is consistent with previous studies at specific loci that demonstrate both active and repressive actions for EHF, depending on the cellular context (22, 45, 46).”
ResultOncogenic activation of ERG: A predominant mechanism in prostate cancer
Srivastava, S., Sreenath, T., Dobi, A., & Petrovics, G. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.91122 · Cited by 68
“[106] Interestingly, NKX3.”
Melling, N., Thomsen, E., Tsourlakis, M. C., Kluth, M., Hube‐Magg, C., Minner, S. J. P., Koop, C., Graefen, M., Heinzer, H., Wittmer, C., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv137 · Cited by 61
Albino, D., Civenni, G., Rossi, S., Mitra, A., Catapano, C. V., & Carbone, G. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12525 · Cited by 55
“Previously we reported that ESE3/EHF is frequently downregulated in prostate tumors and that its loss is associated with robust inflammatory gene signatures [15, 16].”
BackgroundMethodSelf-citationLupold, S. E., & Kumar, B. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.177839 · Cited by 56
TMPRSS2–ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c
Kim, J., Wu, L., Zhao, J. C., Jin, H.-J., & Yu, J. (2013) · Oncogene · doi:10.1038/onc.2013.461 · Cited by 54
Ets homologous factor regulates pathways controlling response to injury in airway epithelial cells
Fossum, S. L., Mutolo, M. J., Yang, R., Dang, H., O’Neal, W. K., Knowles, M. R., Leir, S., & Harris, A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku1146 · Cited by 51
“Previous studies on the function of EHF focused on its role at gene promoters, where it was shown to act as either a gene activator or repressor depending on the cellular context (12,15,16,18).”
BackgroundDuan, Z., Zou, J. X., Yang, P. X., Wang, Y. Z., Borowsky, A. D., Gao, A. C., & Chen, H. (2012) · The Prostate · doi:10.1002/pros.22587 · Cited by 54
Polycomb Repressor Complex 2 in Genomic Instability and Cancer
Veneti, Z., Gkouskou, K. K., & Eliopoulos, A. G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081657 · Cited by 50
“EZH2 is upregulated in prostate cancer through amplification of the EZH2 gene [100], deletion of its negative regulator miR-101 [101], and transcriptional regulation by MYC [102] and ETS gene family members [103].”
BackgroundOncogenic ETS Factors in Prostate Cancer
Nicholas, T. R., Strittmatter, B. G., & Hollenhorst, P. C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_18 · Cited by 58
Albino, D., Falcione, M., Uboldi, V., Temilola, D. O., Sandrini, G., Merulla, J., Civenni, G., Kokanovic, A., Stürchler, A., Shinde, D. A., et al. (2021) · Communications Biology · doi:10.1038/s42003-020-01642-5 · Cited by 46
Self-citationNguyen, P.-N., Violette, P. D., Chan, S. W., Tanguay, S., Kassouf, W., Aprikian, A. G., & Chen, J. Z. (2010) · European Urology · doi:10.1016/j.eururo.2010.11.026 · Cited by 46
“ERG overexpression has recently been shown to inhibit normal prostate differentiation by shutting down androgen signaling [12] and to induce an embryonic stem cell–like dedifferentiation program by turning on EZH2 expression [12–14].”
BackgroundLu, H., Li, G., Zhou, C., Jin, W., Qian, X., Wang, Z., Pan, H., Jin, H., & Wang, X. (2016) · PubMed Central · Cited by 53
Thangapazham, R. L., Sáenz, F., Katta, S., Mohamed, A. A. M., Tan, S., Petrovics, G., Srivastava, S. K., & Dobi, A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-16 · Cited by 47
Liver X Receptors Protect from Development of Prostatic Intra-Epithelial Neoplasia in Mice
Pommier, A., Dufour, J., Alves, G., Viennois, É., de Boussac, H., Trousson, A., Volle, D. H., Caira, F., Val, P., Arnaúd, P., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003483 · Cited by 52
“However, the underlying molecular mechanisms remain unknown as the promoter sequences of Ezh2 are still poorly characterized [25].”
BackgroundCivenni, G., Longoni, N., Costales, P., Dallavalle, C., Inclán, C. G., Albino, D., Núñez, L. E., Morís, F., Carbone, G. M., & Catapano, C. V. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0791 · Cited by 45
Self-citationSPARCL1 suppresses metastasis in prostate cancer
Xiang, Y., Qiu, Q., Jiang, M., Jin, R., Lehmann, B. D., Strand, D. W., Jovanović, B., DeGraff, D. J., Zheng, Y., Yousif, D. A., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.07.008 · Cited by 44
Calcium signalling pathways in prostate cancer initiation and progression
Silvestri, R., Nicolì, V., Gangadharannambiar, P., Crea, F., & Bootman, M. D. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00738-x · Cited by 47
Cai, H., Memarzadeh, S., Stoyanova, T. I., Beharry, Z. M., Kraft, A. S., & Witte, O. N. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0228 · Cited by 43
“The expression of EZH2 is up-regulated by aberrant expression of Myc, ETS transcription factor ERG, or by suppression of microRNA (20-23).”
BackgroundDeletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression
Linn, D. E., Penney, K. L., Bronson, R. T., Mucci, L. A., & Li, Z. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1911 · Cited by 42
“This notion is consistent with the idea of an ETS transcriptional network in prostate tumorigenesis (45).”
Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers
Stelloo, S., Bergman, A. M., & Zwart, W. T. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0032 · Cited by 42
Budka, J. A., Ferris, M. W., Capone, M. J., & Hollenhorst, P. C. (2018) · Genes & Cancer · doi:10.18632/genesandcancer.182 · Cited by 30
“Of these, EHF and ERF have been shown to directly compete with oncogenic ETS at cis-regulatory sequences, opposing the ability of the oncogenic ETS to activate nearby genes [16, 17].”
BackgroundRibarska, T., Bastian, K.-M., Koch, A., & Schulz, W. A. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.160 · Cited by 33
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer
Lefort, K., Ostano, P., Grand, M. M., Calpini, V., Scatolini, M., Farsetti, A., Dotto, G. P., & Chiorino, G. (2016) · Oncotarget · doi:10.18632/oncotarget.10333 · Cited by 31
Self-citationERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
Magistroni, V., Mologni, L., Sanselicio, S., Reid, J. F., Redaelli, S., Piazza, R., Viltadi, M., Bovo, G., Strada, G., Grasso, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028162 · Cited by 30
“Spearman Rank correlation test was performed to analyze the correlation between ERG and PIM1 expression in the available prostate sample data-set (GSE14206) [34].”
BackgroundMethodResultInfluentialChildhood Adversities and Traumata in Lebanon: A National Study
Itani, L. A., Cassir, Y., Fayyad, J. A., Karam, A., & Karam, E. G. (2014) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901410010116 · Cited by 31
Kron, K. J., Trudel, D., Pethe, V. V., Briollais, L., Fleshner, N. E., van der Kwast, T., & Bapat, B. V. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3139 · Cited by 25
“has been shown to correlate with HDAC1 expression and also induces EZH2 expression (37, 38), both of which may cooperate with DNAmethylation to promote a silent chromatin state (30, 39).”
BackgroundZhou, W., Su, Y., Zhang, Y., Han, B., Liu, H., & Wang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584505 · Cited by 29
“First, the mouse xenograft tumors were primarily composed of 22Rv1 cells which were generally ERG negative without any treatment (50, 51).”
BackgroundDovey, Z. S., Nair, S. S., Chakravarty, D., & Tewari, A. K. (2021) · Cancer Reports · doi:10.1002/cnr2.1340 · Cited by 33
Long Noncoding RNA Linc00152 Functions as a Tumor Propellant in Pan-Cancer
Xu, S., Wan, L., Yin, H., Xu, H., Zheng, W., Shen, M., Zhang, Z., & Pang, D. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486170 · Cited by 28
Kaundal, B., Kushwaha, A. C., Srivastava, A. K., Karmakar, S., & Choudhury, S. R. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01177k · Cited by 25
Lin28 Regulates Cancer Cell Stemness for Tumour Progression
Lin, Z., Radaeva, M., Cherkasov, A. R., & Dong, X. (2022) · Cancers · doi:10.3390/cancers14194640 · Cited by 29
“Significant downregulation of ESE3/EHF was reported in PC [119,120].”
BackgroundRahim, S., & Üren, A. (2013) · Europe PMC (PubMed Central) · Cited by 34
Kimura, T., Furusato, B., Miki, J., Yamamoto, T., Hayashi, N., Takahashi, H., Kamata, Y., van Leenders, G. J. L. H., Visakorpi, T., & Egawa, S. (2012) · Pathology International · doi:10.1111/pin.12006 · Cited by 24
Longoni, N., Kunderfranco, P., Pellini, S., Albino, D., Grand, M. M., Pinton, S., D’Ambrosio, G., Sarti, M., Sessa, F., Chiorino, G., et al. (2012) · Oncogene · doi:10.1038/onc.2012.245 · Cited by 23
Self-citationMolecular and Clinical Relevance of ZBTB38 Expression Levels in Prostate Cancer
de Dieuleveult, M., Marchal, C., Jouinot, A., Letessier, A., & Miotto, B. (2020) · Cancers · doi:10.3390/cancers12051106 · Cited by 25
“Cancers 2020, 12, 1106 5 of 22 Cancers 2020, 12, 1106 6 of 22 In Kunderfranco’s cohort (GSE14206) [50], we observed a tendency between low ZBTB38 expression levels and high Gleason score (p = 0.065) and a significant correlation with patient’s age (p = 0.044).”
BackgroundInfluentialBismar, T. A., Alshalalfa, M., Petersen, L. F., Teng, L. H., Gerke, T. A., Bakkar, A., Almami, A., Liu, S., Dolph, M., Mucci, L. A., et al. (2013) · British Journal of Urology · doi:10.1111/bju.12262 · Cited by 26
Evaluation of ERG responsive proteome in prostate cancer
Tan, S., Furusato, B., Fang, X., He, F., Mohamed, A. A. M., Griner, N. B., Sood, K., Saxena, S., Katta, S., Young, D., et al. (2013) · The Prostate · doi:10.1002/pros.22731 · Cited by 24
Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes
Jillson, L. K., Yette, G. A., Laajala, T. D., Tilley, W. D., Costello, J. C., & Cramer, S. D. (2021) · Cancers · doi:10.3390/cancers13133272 · Cited by 20
Morgan, M. P., Finnegan, E., & Das, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.10.002 · Cited by 21
Loss of EHF facilitates the development of treatment-induced neuroendocrine prostate cancer
Long, Z., Deng, L. H., Li, C., He, Q., He, Y., Hu, X., Cai, Y., & Gan, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03326-8 · Cited by 20
Liu, S., Wang, X., Qin, W., Genchev, G. Z., & Lu, H. J. (2018) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-018-0300-9 · Cited by 17
Kaundal, B., Srivastava, A. K., Dev, A., Mohanbhai, S. J., Karmakar, S., & Choudhury, S. R. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01071 · Cited by 17
Role of Signaling Transduction Pathways in Development of Castration-Resistant Prostate Cancer
Inoue, T., & Ogawa, O. (2011) · Prostate Cancer · doi:10.1155/2011/647987 · Cited by 19
“1, a prostate-specific homeobox protein involved in prostate development and differentiation, through induction of EZH2 expression [62].”
BackgroundInterrogating genomic and epigenomic data to understand prostate cancer
Kim, J., & Yu, J. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.003 · Cited by 20
“Through PCR analysis of ERG ChIP-enriched DNA they subsequently demonstrated that ERG directly induces EZH2 expression [80].”
Histone Modifications, Stem Cells and Prostate Cancer
Crea, F., Clermont, P., Mai, A., & Helgason, C. D. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990522 · Cited by 17
“ETS family transcription factors can either activate or repress the expression of EZH2 and about 80% of prostate tumors have one or more aberrantly expressed ETS gene [113].”
BackgroundCivenni, G., Albino, D., Shinde, D. A., Vázquez, R., Merulla, J., Kokanovic, A., Mapelli, S. N., Carbone, G. M., & Catapano, C. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00385 · Cited by 17
Self-citationSimilarity of markers identified from cancer gene expression studies: observations from GEO
Shi, X., Shen, S., Liu, J., Huang, J., Zhou, Y., & Ma, S. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbt044 · Cited by 15
Archer, L. K., Frame, F. M., & Maitland, N. J. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.05.006 · Cited by 18
Cacciatore, A., Shinde, D. A., Musumeci, C., Sandrini, G., Guarrera, L., Albino, D., Civenni, G., Storelli, E., Mosole, S., Federici, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50908-7 · Cited by 16
“All these events foster functional crosstalk between ERG, EZH2, and AR, leading to transcriptional and chromatin reprogramming 17 – 19 .”
BackgroundSelf-citationYan, W., Jamal, M., Tan, S., Song, Y., Young, D., Chen, Y., Katta, S., Ying, K., Ravindranath, L., Woodle, T., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27294 · Cited by 15
“These genes were selected based on their association with cancer, specifically prostate cancer, according to the following criteria, supported by at least two publications: (1) have significant differential gene expression in prostate tumor versus normal comparison based on microarray gene expression profiling (data a…”
BackgroundBernreuther, C., Daghigh, F., Möller, K., Hube‐Magg, C., Lennartz, M., Lutz, F., Rico, S. D., Fraune, C., Dum, D., Luebke, A. M., et al. (2020) · Pathology & Oncology Research · doi:10.1007/s12253-020-00861-9 · Cited by 14
Concurrent Down-Regulation of PTEN and NKX3.1 Expression in Iranian Patients with Prostate Cancer
Nodouzi, V., Nowroozi, M., Hashemi, M., Javadi, G., & Mahdian, R. (2015) · International braz j urol · doi:10.1590/s1677-5538.ibju.2014.0036 · Cited by 12
“(30) examined the expression of transcription factor ERG (ETS related gene), NKX3.”
BackgroundTamura, R. E., Paccez, J. D., Duncan, K., Morale, M. G., Simabuco, F. M., Dillon, S. T., Correa, R. G., Gu, X., Libermann, T. A., & Zerbini, L. F. (2016) · Oncotarget · doi:10.18632/oncotarget.7355 · Cited by 13
“com/oncotarget as oncogenes in prostate cancer [2-4].”
Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer
Berglund, A., Rounbehler, R. J., Gerke, T. A., Awasthi, S., Cheng, C., Takhar, M. M., Davicioni, E., Alshalalfa, M., Erho, N., Klein, E. A., et al. (2018) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-018-0103-4 · Cited by 13
Lorenzoni, M., Felice, D. D., Beccaceci, G., Donato, G. D., Foletto, V., Genovesi, S., Bertossi, A., Cambuli, F., Lorenzin, F., Savino, A., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215612 · Cited by 14
LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?
Cariello, M., Ducheix, S., Maqdasy, S., Baron, S., Moschetta, A., & Lobaccaro, J. A. (2018) · Nuclear Receptor Signaling · doi:10.1177/1550762918801070 · Cited by 14
EHF is a novel regulator of cellular redox metabolism and predicts patient prognosis in HNSCC
Oyelakin, A., Nayak, K. B., Glathar, A. R., Gluck, C. B., Wrynn, T., Tugores, A., Romano, R., & Sinha, S. (2022) · NAR Cancer · doi:10.1093/narcan/zcac017 · Cited by 10
Dobi, A., Sreenath, T., & Srivastava, S. K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6182-1_19 · Cited by 9
“The results of further investigations suggested direct involvement of ERG in disrupting the normal epigenetic regulatory function of EZH2 gene that is a key component of the polycomb group II (PcG II) [ 6, 55, 56 ] .”
BackgroundChromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
Patil, S., Forster, T., Reutlinger, K., Kopp, W., Versemann, L., Spitalieri, J., Gaedcke, J., Ströbel, P., Singh, S. K., Ellenrieder, V., et al. (2021) · Cells · doi:10.3390/cells10123463 · Cited by 12
Cancer on motors: How kinesins drive prostate cancer progression?
Wang, J., Zhang, F.-H., Liu, Z. L., Tang, Y.-J., Li, J., & Xie, L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116229 · Cited by 11
Metadata
- Authors
- Kunderfranco, P., Mello-Grand, M., Cangemi, R., Pellini, S., Mensah, A., Albertini, V., Malek, A., Chiorino, G., Catapano, C. V., & Carbone, G. M.
- Affiliations
- Istituto Oncologico della Svizzera Italiana (CH)
- Fondazione Edo ed Elvo Tempia (IT)
- Corresponding author
- Carbone, Giuseppina M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-05-10
- Volume
- 5
- Issue
- 5
- Pages
- e10547
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2866657
- OpenAlex
- W1982538300
- Cited by
- 143
- References
- 49
- Citations by year
- 2025: 5 · 2024: 4 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 7 · 2014: 8 · 2013: 19 · 2012: 16
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Uni Genf
- Funders
- National Science Foundation
- Compagnia di San Paolo
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A, 118113)
- Oncosuisse
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ETS transcription factors, prostate cancer, EZH2, NKX3.1, epigenetic silencing, ERG, Polycomb group proteins, tumor suppressor, prostate tumorigenesis, transcriptional regulation, tumor subtypes, gene expression signatures
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Transcriptional Regulator ERG, Aged, Cell Movement, DNA-Binding Proteins, Histones, Humans, Lysine, Male, Methylation, Middle Aged, Models, Genetic, Prostatic Neoplasms, Transcription Factors, Transcription, Genetic, Trans-Activators, Up-Regulation, Gene Expression Regulation, Neoplastic, Homeodomain Proteins, Gene Silencing, Gene Expression Profiling, Anoikis, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-ets, Gene Knockdown Techniques, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.